BTIG analyst Marie Thibault raised the firm’s price target on iRhythm (IRTC) to $135 from $120 and keeps a Buy rating on the shares after its ...

BTIG upgraded Snowflake Inc (NYSE:SNOW) to "Buy" from "Neutral" and introduced a $220 price target on improving demand trends and potential AI-driven growth.

NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will host its annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Tuesday, February 11 through Wednesday ...

BTIG raised the firm’s price target on Guardant Health (GH) to $60 from $55 and keeps a Buy rating on the shares after its Q4 earnings beat and ...

Investing.com -- BTIG downgraded General Dynamics Corporation (NYSE:GD)to Neutral given the ongoing regulatory hurdles and supply chain disruptions that could hamper growth in 2025. The brokerage ...

Well, in a note published on Sunday, BTIG chartist guru Jonathan Krinsky observed that Friday's action had already suggested that the semiconductor sector (SMH) — which is down 7% early Monday ...

As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low of $4.80 to a high of $31.50. The average price target represents an ...

BTIG highlights Wingstop (WING) as a top pick ahead of earnings, citing strong unit growth, supply chain benefits, & robust ...

But before that let's have a chartist view from BTIG's technical guru Jonathan Krinsky. He notes that the S&P 500's rally off this week's lows is quite impressive and sets up the stock barometer ...

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report), with a price ...